ArgonautArgonautArgonautArgonaut
  • About Us
    • Business Model
    • Regulation
    • Community
    • Jason and the Argonauts
    • Disclaimer and Disclosure
    • COVID-19 Visitor Requirements
  • Corporate Finance
  • Stockbroking & Research
    • Stockbroking
    • Research
    • Best Execution Policy
    • Administration Forms
    • Open an Account
  • Special Situations
  • News
    • Latest News
    • Morning Notes
    • Latest Research
  • Contact
    • Careers
      • Advisers
      • Graduate Program
      • Internship Program

Argonaut congratulates Botanix Pharmaceuticals on Placement

By admin | Uncategorized | 0 comment | 5 October, 2017 | 0

Argonaut has acted as Lead Manager to Botanix Pharmaceuticals Ltd (ASX: BOT) (“Botanix”) in its oversubscribed placement of A$7.4 million to new and existing institutional and sophisticated investors.

The funds raised under the placement provides financial capacity for Botanix to execute on its strategy to advance the clinical development of Botanix’s dermatology products, BTX1503 and BTX1204, and to pursue the strategy of commercialising the Permetrex TM technology. The Phase 1A trial of BTX1503 is schedule to commence soon and the company expects to fast-track the clinical development of BTX 1204 which is a topical treatment for moderate to severe atopic dermatitis.

Botanix’s Executive Director, Matthew Callahan said: “The overwhelming support for the Placement is a clear vote of confidence from the institutional and sophisticated investment community in relation to Botanix’s business strategy, speed of clinical development and unique focus on using synthetically derived cannabidiol and the PermetrexTM delivery technology in the novel treatment of dermatology conditions.

Investor interest in our transaction reflects the confidence in the Botanix program and management’s plans to accelerate initial in-human trials and shorten the product development cycle. We thank all the investors who have supported Botanix.”

Argonaut is delighted to provide ongoing support to Botanix and looks forward to working with the Company to continue to create further value for stakeholders.

Additional information regarding Botanix can be found on the company’s website at www.botanixpharma.com.

No tags.

Related Posts

  • 1H 2022 Metals and Mining IPOs Review

    By Wendy McEvoy | 0 comment

    After a near record 106 Metals and Mining (M&M) listings on the ASX in 2021, the pace has been maintained with a further 44 hitting the screens in the first half of 2022. Recent marketRead more

  • WIA Gold Ltd (WIA) – Namibian Gold Find

    By Wendy McEvoy | 0 comment

    At an early stage, the Kokoseb gold discovery shows potential to develop into a valuable project. To access the full report please log in under the Client Area at the bottom of this page.   Argonaut’sRead more

  • Ausgold Limited (AUC) – Growing in Confidence

    By Wendy McEvoy | 0 comment

    Following completion of a 27 km RC and diamond drill programme, Ausgold has updated its Resource estimate for the Katanning Gold Project. The update has added 320kozs to the overall estimate for 2.2Mozs @ 1.2Read more

  • $30 million institutional placement sets up Lunnon Metals for growth in 2022

    By Wendy McEvoy | 0 comment

    Argonaut acted as Joint Lead Manager to a $30m institutional placement (“Placement”) for Lunnon Metals Ltd (ASX:LM8). The Placement was strongly supported by new institutional investors and existing shareholders. Funds from the Placement will be applied towards resourceRead more

  • $157m Scheme of Arrangement between Bardoc and St Barbara

    By Wendy McEvoy | 0 comment

    Argonaut acted as Financial Advisor to Bardoc Gold Limited (ASX: BDC) on its all scrip $157 million Scheme of Arrangement with St Barbara Limited (ASX: SBM) and concurrent demerger of Edge Minerals. The transaction will logically combineRead more

  • About Us
    • Business Model
    • Regulation
    • Community
    • Jason and the Argonauts
    • Disclaimer and Disclosure
    • COVID-19 Visitor Requirements
  • Corporate Finance
  • Stockbroking & Research
    • Stockbroking
    • Research
    • Best Execution Policy
    • Administration Forms
    • Open an Account
  • Special Situations
  • News
    • Latest News
    • Morning Notes
    • Latest Research
  • Contact
    • Careers
      • Advisers
      • Graduate Program
      • Internship Program
Argonaut

Argonaut | The Natural Choice in Resources.
© 2022 Argonaut.

Corporate Finance
Stockbroking & Research
Contact Us

Argonaut | Perth

Level 30, Allendale Square, 77 St Georges Terrace Perth, WA, 6000 Australia

clientservices@argonaut.com

ABN 72 108 330 650

Argonaut | Login

Client Area Help
Register for Access to Client Area
Privacy Policy
Financial Services Guide 
Website Disclaimer

Copyright 2021 | Website ⚡ by Start Digital